[go: up one dir, main page]

ES2114562T3 - Forma de dosificacion para distribucion retardada de farmacos. - Google Patents

Forma de dosificacion para distribucion retardada de farmacos.

Info

Publication number
ES2114562T3
ES2114562T3 ES92914277T ES92914277T ES2114562T3 ES 2114562 T3 ES2114562 T3 ES 2114562T3 ES 92914277 T ES92914277 T ES 92914277T ES 92914277 T ES92914277 T ES 92914277T ES 2114562 T3 ES2114562 T3 ES 2114562T3
Authority
ES
Spain
Prior art keywords
delayed
dosage form
dosage
pharmacy
distribution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92914277T
Other languages
English (en)
Inventor
Frank Jao
Patrick S L Wong
Hoa T Huynh
Kathy Mcchesney
Pamela K Wat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ES2114562T3 publication Critical patent/ES2114562T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/556Angiotensin converting enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Reciprocating, Oscillating Or Vibrating Motors (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTA UNA PREPARACION MEDICINAL DE DOSIFICACION (10) QUE CONSTA DE UN ELEMENTO (17) PARA RETARDAR EL SUMINISTRO DE UN FARMACO (16) DE LA PREPARACION MEDICINAL DE DOSIFICACION (16) TRAS LA ADMINISTRACION DE LA PREPARACION MEDICINAL DOSIFICACION (10) A UN PACIENTE QUE NECESITE UNA TERAPIA CON EL FARMACO (16).
ES92914277T 1991-06-27 1992-06-26 Forma de dosificacion para distribucion retardada de farmacos. Expired - Lifetime ES2114562T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/722,622 US5160744A (en) 1991-06-27 1991-06-27 Verapmil therapy

Publications (1)

Publication Number Publication Date
ES2114562T3 true ES2114562T3 (es) 1998-06-01

Family

ID=24902641

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92914277T Expired - Lifetime ES2114562T3 (es) 1991-06-27 1992-06-26 Forma de dosificacion para distribucion retardada de farmacos.

Country Status (18)

Country Link
US (1) US5160744A (es)
EP (1) EP0591389B1 (es)
JP (1) JP3718522B2 (es)
KR (1) KR0137731B1 (es)
AT (1) ATE165000T1 (es)
AU (1) AU654871B2 (es)
CA (1) CA2105165C (es)
DE (1) DE69225135T2 (es)
ES (1) ES2114562T3 (es)
FI (1) FI110919B (es)
GR (1) GR3026674T3 (es)
IE (1) IE922122A1 (es)
MX (1) MX9203443A (es)
NO (1) NO306377B1 (es)
NZ (1) NZ243343A (es)
PT (1) PT100635B (es)
WO (1) WO1993000071A1 (es)
ZA (1) ZA924772B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5854254A (en) * 1994-03-30 1998-12-29 North Shore University Hospital Male contraceptives
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
EP0910375B1 (en) * 1996-06-24 2002-05-02 Merck & Co., Inc. A composition of enalapril and losartan
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
KR100827254B1 (ko) 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
WO2001047500A1 (en) * 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven drug dosage form
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
EP1280533A2 (en) * 2000-05-11 2003-02-05 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) * 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
CA2481236A1 (en) * 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
WO2006046114A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
CA2591247A1 (en) * 2004-12-09 2006-06-15 Celgene Corporation Treatment of patients suffering from a disease having a family history or diagnosis of tics or tourette's syndrome with d-threo methylphenidate
DE102005031577A1 (de) 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN102091052B (zh) * 2009-12-15 2012-11-07 北京协和药厂 双环醇双层渗透泵控释片剂及其制备方法
CN102293760B (zh) * 2011-03-04 2015-03-18 上海医药集团股份有限公司 一种单硝酸异山梨酯择时控释制剂及其制备方法
IN2014DN09045A (es) 2012-05-07 2015-05-22 Bayer Pharma AG
UY34856A (es) 2012-07-03 2013-12-31 Bayer Pharma AG Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4318400A (en) * 1980-01-18 1982-03-09 Alza Corporation Medical infusor
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
US4842867A (en) * 1986-05-09 1989-06-27 Alza Corporation Pulsed drug delivery of doxylamine
US4948592A (en) * 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4950486A (en) * 1987-10-02 1990-08-21 Alza Corporation Dosage form for treating cardiovascular diseases
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US4966769A (en) * 1988-06-02 1990-10-30 Alza Corporation Method for delivering dosage form for diltiazem
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery

Also Published As

Publication number Publication date
NO934487L (no) 1993-12-17
FI110919B (fi) 2003-04-30
ATE165000T1 (de) 1998-05-15
NO306377B1 (no) 1999-11-01
IE922122A1 (en) 1992-12-30
DE69225135T2 (de) 1998-08-20
US5160744A (en) 1992-11-03
ZA924772B (en) 1993-03-31
DE69225135D1 (de) 1998-05-20
AU654871B2 (en) 1994-11-24
JP3718522B2 (ja) 2005-11-24
NZ243343A (en) 1994-12-22
NO934487D0 (no) 1993-12-09
CA2105165A1 (en) 1992-12-28
CA2105165C (en) 2004-03-16
GR3026674T3 (en) 1998-07-31
EP0591389B1 (en) 1998-04-15
FI935844L (fi) 1993-12-23
AU2255092A (en) 1993-01-25
KR0137731B1 (ko) 1998-05-15
MX9203443A (es) 1992-12-01
FI935844A0 (fi) 1993-12-23
EP0591389A1 (en) 1994-04-13
WO1993000071A1 (en) 1993-01-07
JPH06508838A (ja) 1994-10-06
PT100635B (pt) 1999-07-30
PT100635A (pt) 1993-09-30

Similar Documents

Publication Publication Date Title
ES2114562T3 (es) Forma de dosificacion para distribucion retardada de farmacos.
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
IT8767796A0 (it) Forma farmaceutica di dosaggio per somministrazione orale con erogazione controllata di un ingrediente attivo
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
FI940787A7 (fi) Annostusmuoto lääkkeen annostelemiseksi lyhyessä ajanjaksossa
ES2194210T3 (es) Forma de dosificacion para suministrar una dosis ascendente de farmaco.
ES2153338T1 (es) Dosificacion mejorada de dosis multiples de medicamentos.
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
ES2008580A6 (es) Forma de dosificacion para la liberacion rapida y lenta de agente beneficioso.
AR028299A1 (es) Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
ES2073677T3 (es) Revestimientos de liberacion sostenida y enmascaramiento del sabor para productos farmaceuticos.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2181417T3 (es) Formulacion de capsulas o tabletas de efavirenz de disolucion rapida usando super-desintegrantes.
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
FI905684A0 (fi) Farmaceutisk doseringsform foer utdelning av medicin aot fiskar.
KR930007441A (ko) 의약품
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
ES2054333T3 (es) Forma de dosificacion para administrar un antagonista del calcio.
FR2356425A1 (fr) Application a titre de medicaments de derives organiques de la montmorillonite
ES2078838A1 (es) Procedimiento para preparar una composicion a base de clozapina.
MY100780A (en) Azumolene dosage form.
GB950162A (en) Medicines for the treatment of hepatic disorders
ES2069897T3 (es) Forma de dosificacion para administrar un farmaco para realizar una terapia circadiana.
BR9912260A (pt) Emplastro contendo um sistema terapêutico transdérmico e dose única para ministração
DK117291D0 (da) Doseringsform til oral indgift af laegemiddelstoffer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 591389

Country of ref document: ES